Low Grade Serous Ovarian Cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Low-grade serous ovarian cancer (LGSC), which accounts for about 10% of serous carcinomas, is a morphologically and molecularly distinct subtype of ovarian cancer. Women frequently present at a younger age and have a longer clinical course compared to the more common, high-grade serous ovarian cancer. LGSOC, which can arise from serous low-malignant potential ovarian tumors as well as from the ovary or peritoneum on its own, accounts for about 5% of serous ovarian malignancies. Serous ovarian carcinoma (SOC), which is further broken down into high- and low-grade subtypes, is the most common type of EOC. The cornerstone of initial treatment for LGSOC is still surgery. The importance of receiving the appropriate surgical evaluation at the time of initial presentation is highlighted by the fact that patients with LGSOC who are still ill at the conclusion of their initial treatment have a worse prognosis than those with high-grade serous ovarian cancer.

Description

The 10% of serous carcinomas that are low-grade serous ovarian cancer (LGSC) are distinct from other ovarian cancer subtypes in terms of morphology and molecular makeup. Women frequently present at a younger age and have a prolonged clinical course compared to the more common, high-grade serous ovarian cancer. The mainstays of treatment for the majority of patients with LGSC are currently debulking surgery and platinum/taxane chemotherapy, just like with other epithelial ovarian cancer subtypes. Although platinum-based chemotherapy is now being questioned due to poor response rates in LGSC in both upfront and recurrent settings, primary surgical cytoreduction to no visible residual cancer still remains a crucial prognostic marker. Since most LGSC express steroid hormone receptors, some patients-in particular, those who displayed disease symptoms even after surgery-may profit from endocrine maintenance therapy following chemotherapy. In the context of recurrence, hormone therapies may be able to stabilize the condition with little negative side effects, but objective response rates are still subpar. To increase response rates, researchers are examining different strategies, such as pairing with CDK4/6 inhibitors. LGSC exhibits the majority of the mitogen-activated protein kinase pathway's activating somatic mutations for KRAS, BRAF, and NRAS. Trametinib, a MEK inhibitor, has proven to be more effective than hormone therapy and chemotherapy. For the treatment of LGSC, ongoing research focuses on immunotherapy, anti-angiogenic medications, and combination targeted therapies.

Low Grade Serous Ovarian Cancer (Epidemiology)

The LGSOC subtype of serous ovarian malignancies, which accounts for about 5% of all serous ovarian malignancies, can arise either from serous low-malignant potential ovarian tumors or directly from the ovary or peritoneum. Serous ovarian carcinoma (SOC), which is further broken down into high- and low-grade subtypes, is the most common type of EOC. Generally speaking, LGSOC affects younger women than HGSOC, has a better prognosis, and is more chemoresistant. LGSOCs frequently arise in serous borderline tumors (SBOT), which have high rates of BRAF (0-33%, average 5%) and KRAS (19-55%) mutations. Evidence suggests that NRAS mutations may be an oncogenic driver in the emergence of these tumors. The oestrogen receptor (ER) and progesterone receptor (PR) are expressed more frequently in LGSOCs, which are frequently TP53 wild type. When it comes to SOC and EOC, LGSOC accounts for 6-10% and 8-12%, respectively. With a median age of 55 vs. 63 years (mean of 55.5 vs. 62.6 years) and a higher likelihood of being premenopausal, women are diagnosed with HGSOC more frequently than men, indicating a hormonal role in pathogenesis.

Low Grade Serous Ovarian Cancer-Current Market Size & Forecast Trends

The market for low-grade serous ovarian cancer (LGSOC) is projected to grow from approximately USD 179.6 million in 2023 to around USD 363.7 million by 2034, reflecting a compound annual growth rate (CAGR) of 6.62% during this period. This growth is driven by the rising prevalence of LGSOC, advancements in treatment options, and increasing awareness of the disease. The market is characterized by the adoption of targeted therapies, including kinase inhibitors and hormone therapies, which are showing promise in managing this cancer subtype. Additionally, the growing utilization of biomarker testing and real-time molecular profiling technologies is expected to enhance early diagnosis and treatment responses. The United States represents the largest market for LGSOC treatment, followed by key markets in Europe and Japan. As ongoing research continues to develop new therapeutic strategies, the LGSOC market is well-positioned for significant expansion through 2035.

The cornerstone of initial LGSOC treatment is still surgery. To determine whether primary debulking surgery is an option, every patient should go through a preliminary evaluation by a gynecologic oncologist. For some patients who are deemed unsuitable for primary debulking surgery due to the severity of their condition or coexisting medical conditions, neoadjuvant chemotherapy with a platinum/taxane-based doublet combined with interval cytoreductive surgery may be an option. It is important to keep in mind, though, that LGSOC frequently has a calcific radiographic appearance and may take on a more calcified appearance without significant radiographic shrinkage in response to chemotherapy, which can make it challenging at times to gauge response to systemic therapy. The importance of receiving the appropriate surgical evaluation at the time of initial presentation is highlighted by the fact that patients with LGSOC who are still ill at the conclusion of their initial treatment have a worse prognosis than those with high-grade serous ovarian cancer. Following staging surgery, patients with stage II-IV disease receive chemotherapy for six cycles with a platinum/taxane-based doublet. Retrospective studies have revealed disappointing response rates to chemotherapy in LGSOC, despite the fact that due to the calcific nature of this disease, treatment effect is not always measurably by conventional metrics for radiographic response. Bevacizumab is now FDA-approved for use in conjunction with chemotherapy for the initial treatment of patients with stage III or IV ovarian cancer following surgery. Chemotherapy is administered either with or without bevacizumab. Patients with stage IA or IB disease should be observed after a full gross resection of the disease. Patients with stage IC disease are either treated with observation only or adjuvant platinum-based chemotherapy for three to six cycles.

Report Highlights

Low Grade Serous Ovarian Cancer- Current Market Trends

Low Grade Serous Ovarian Cancer- Current & Forecasted Cases across the G8 Countries

Low Grade Serous Ovarian Cancer- Market Opportunities and Sales Potential for Agents

Low Grade Serous Ovarian Cancer- Patient-based Market Forecast to 2035

Low Grade Serous Ovarian Cancer- Untapped Business Opportunities

Low Grade Serous Ovarian Cancer- Product Positioning Vis-a-vis Competitors' Products

Low Grade Serous Ovarian Cancer- KOLs Insight